Generic Healthcare Research & Development

—Generic
Healthcare Ltd Research & Development is a non-profit organization carrying
out basic, preclinical, and translational research to deliver improved
diagnostics and therapeutics for human disease.
—Generic
R&D funds itself through research grants and out-licensing of proprietary
technologies.
—New
discoveries and IP generated by Generic R&D will be out-licensed or,
potentially, developed in house.
—Women’s health
—preeclampsia
—ovarian
cancer
—Fibrotic disease
—post-MI
heart failure
—non-alcoholic
steatohepatitis (NASH, “fatty liver”)
—idiopathic
pulmonary fibrosis (IPF)
—Preeclampsia
—affects 1 in 5-10 of pregnancies in US
—affects >10% of pregnancies in developing countries
—can be life-threatening
—economic cost is high
—increased hospitalization cost
—delayed development
—Despite the high medical need, there is no diagnostic test and no approved therapeutic for preeclampsia.
—Ovarian cancer
—5th leading cause of cancer deaths in US women
—239,000 cases, 152,000 deaths worldwide (2012)
—5-year survival is only 20%
—due to late diagnosis and recurrent cancer
—standard therapy is combination of platinum-based drugs and taxol
—resistance and side effects are major issues
—New drugs are urgently needed.
—2 small-molecule drugs with anti-cancer potential
—TMQ
—being evaluated by Dr. Uddin’s group in collaboration with Japanese university
—results to date demonstrate activity in ovarian cancer
—work is being initiated with an animal model, using a patient-derived xenograft (PDX) model developed in Dr. Uddin’s lab.
—CINO
—a naturally occurring bufadienolide (a steroid)
—strong activity in vitro and in animal model
—derivatives have been designed and will be synthesized
—if derivatives show improved activity, a patent application will be filed.
—The activity of these drugs may make them useful beyond ovarian cancer.
—Relaxin H2B733: peptide derivative of human relaxin
—strong anti-fibrotic activity
—fewer side effects than relaxin itself
—activity demonstrated in animal models of 3 fibrotic diseases
—acute heart failure
—idiopathic pulmonary fibrosis (IPF)
—renal fibrosis
—potential therapeutic for other indications
—non-alcoholic steatohepatitis (NASH)
—preeclampsia
—We are engaged in licensing discussions with the institute holding the technology.
—As a non-profit engaged in basic and clinical research, Generic R&D can receive favorable tax treatment.
—Generic R&D will be applying for grant funding for which for-profit entities will not be eligible. 
—

Prof. M. Nasir Uddin, PhD, FAHA is serving as a faculty member in a USA Medical University and also serving as a Research Director- Neonatal-Perinatal Medicine Fellowship Program and Scientific Director-OB/GYN Research at teaching hospital in USA. Dr. Uddin is the Founder Executive & Scientific Director of Orion Institute for Translational Medicine and Founder and Chief Executive Officer (CEO) of Artemis Biotechnologies, LLC., Temple, Texas.  Dr. Uddin is a nationally and international renowned biomedical scientist. He is travelling all the globe for consultancy and teaching in his field of expertise. In addition to teaching national and international level as a visiting professor, Dr. Uddin’s research currently focuses on two diseases of high unmet medical need: preeclampsia (hypertension during pregnancy) and gynecologic cancer; ovarian cancer. A major long-term goal of his lab is to determine the pathogenesis and molecular signaling in preeclampsia and ovarian cancer and to evaluate potential therapeutic interventions. With worldwide collaborations with universities, research institutes, biotechnology, and pharmaceutical companies, Dr. Uddin has active and pending National Institute of Health (NIH) and several foundation funding for continuing his research activities. Dr. Uddin is a Fellow of the American Heart Association and serves as a Councilor of the Central Texas Society for Clinical and Translational Research. He has published more than 200 peer reviewed articles and has presented more than 500 abstracts in national and international meetings.  Dr. Uddin mentored more than 100 medical students, medical residents and fellows, graduate students and postdoctoral fellows. He is a member of several professional societies and a peer review member of several Journals and funding agencies at USA and several other countries.

Dr. Afroze obtained BS and MS in Biology minor in Biochemistry from University of Dhaka, Bangladesh. She obtained PhD in Microbial Biotechnology from Gifu University, Japan. Dr. Afroze worked as a research associate at Texas A&M Health Science Center College of Medicine. She is serving as a director of research at Orion Institute of Translational medicine and Artemis Biotechnologies LLC.  Dr. Afroze accomplished a significant advancement on the Cinobufotalin-induced cellular mechanism of ovarian cancer cell function. Her research findings provide a clue to design the CINO-induced therapeutic intervention of ovarian cancer. Dr. Afroze has published a number of peer reviewed articles and has presented a number of abstracts in national and international meetings.

https://www.artemisbiotech.org